Phase 1B Study of RiVax, a Vaccine to Prevent the Toxic Effects of Ricin
| Status: | Completed |
|---|---|
| Conditions: | Healthy Studies |
| Therapuetic Areas: | Other |
| Healthy: | No |
| Age Range: | 18 - 31 |
| Updated: | 5/27/2013 |
| Start Date: | March 2008 |
| End Date: | January 2013 |
Phase 1 Study of the Safety and Immunogenicity of RiVax With Alum in Healthy Adults
Dose escalation study: 3 dose groups. 5 patients in each dose group, then 15 more patients
in "best" group. 3 vaccinations in volunteers, at 0 6 and 16 weeks.
Inclusion Criteria:
- healthy volunteers aged 18-31, m or f
Exclusion Criteria:
- immunodeficiency
- pregnant
- chronic disease
- parental IgG
- abnormal labs
- drug use
- hiv
- hep c
- hep b
We found this trial at
1
site
Click here to add this to my saved trials
